Source: Eur Respir J 2010; 36: 870-877
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Oxlade O., Schwartzman K., Pai M., Heymann J., Benedetti A., Royce S., Menzies D.. Predicting outcomes and drug resistance with standardised treatment of active tuberculosis. Eur Respir J 2010; 36: 870-877

Member's Comments

No comment yet.

Related content which might interest you: Predicting outcomes and drug resistance with new standardised treatment Source: Eur Respir J 2011; 37: 974 Year: 2011 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance Source: Eur Respir J 2014; 43: 566-581 Year: 2013 Long term treatment outcome in multi drug resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Long-term results of drug resistant tuberculosis treatment Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006 Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Factors affecting outcomes of individualised treatment for drug resistant tuberculosis in an endemic region> Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 Is standardized treatment appropriate for non-XDR multiple drug resistant TB? Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Predictors of treatment outcome in multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 571-574 Year: 2015 The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 569-571 Year: 2015 Impact of smoking on outcome of treatment of tuberculosis in patients taking intermittent treatment of tuberculosis under India‘s revised tuberculosis control program Source: Annual Congress 2008 - Health effects of passive smoking and of a smoking ban Year: 2008 The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 The peculiarities of course and treatment of pulmonary tuberculosis with initial drug resistance Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003 Antituberculosis drug-induced hepatotoxicity: influence on the management and outcome of active tuberculosis (TB) Source: Annual Congress 2007 - Epidemiology of tuberculosis II Year: 2007 Standardized second-line anti-TB treatment of multidrug-resistant tuberculosis during pregnancy; maternal and neonatal safety and outcome Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010